Placebo influences on dyskinesia in Parkinson's disease
Identifieur interne : 001B13 ( Istex/Curation ); précédent : 001B12; suivant : 001B14Placebo influences on dyskinesia in Parkinson's disease
Auteurs : Christopher G. Goetz [États-Unis] ; Eugene Laska [États-Unis] ; Christine Hicking [Allemagne] ; Philippe Damier [France] ; Thomas Müller [Allemagne] ; John Nutt [États-Unis] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-04-15.
English descriptors
Abstract
Clinical features that are prognostic indicators of placebo response among dyskinetic Parkinson's disease patients were determined. Placebo‐associated improvements occur in Parkinsonism, but responses in dyskinesia have not been studied. Placebo data from two multicenter studies with identical design comparing sarizotan to placebo for treating dyskinesia were accessed. Sarizotan (2 mg/day) failed to improve dyskinesia compared with placebo, but both treatments improved dyskinesia compared with baseline. Stepwise regression identified baseline characteristics that influenced dyskinesia response to placebo, and these factors were entered into a logistic regression model to quantify their influence on placebo‐related dyskinesia improvements and worsening. Because placebo‐associated improvements in Parkinsonism have been attributed to heightened dopaminergic activity, we also examined the association between changes in Parkinsonism and dyskinesia. Four hundred eighty‐four subjects received placebo treatment; 178 met criteria for placebo‐associated dyskinesia improvement and 37 for dyskinesia worsening. Older age, lower baseline Parkinsonism score, and lower total daily levodopa doses were associated with placebo‐associated improvement, whereas lower baseline dyskinesia score was associated with placebo‐associated worsening. Placebo‐associated dyskinesia changes were not correlated with Parkinsonism changes, and all effects in the sarizotan group were statistically explained by the placebo‐effect regression model. Dyskinesias are affected by placebo treatment. The absence of correlation between placebo‐induced changes in dyskinesia and Parkinsonism argues against a dopaminergic activation mechanism to explain placebo‐associated improvements in dyskinesia. The magnitude and variance of placebo‐related changes and the factors that influence them can be helpful in the design of future clinical trials of antidyskinetic agents. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21897
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B15
Links to Exploration step
ISTEX:26A53AAFCA642D9FC0D0DC629121E408271C161ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Placebo influences on dyskinesia in Parkinson's disease</title>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><mods:affiliation>Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
</affiliation>
<affiliation wicri:level="2"><mods:affiliation>Rush University Medical Center, Suite 755, 1725 West Harrison Street, Chicago, IL</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>Rush University Medical Center, Suite 755, 1725 West Harrison Street, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Laska, Eugene" sort="Laska, Eugene" uniqKey="Laska E" first="Eugene" last="Laska">Eugene Laska</name>
<affiliation wicri:level="1"><mods:affiliation>New York University School of Medicine, New York, New York, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New York University School of Medicine, New York, New York</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Nathan Kline Institute, Orangeburg, New York, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Nathan Kline Institute, Orangeburg, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hicking, Christine" sort="Hicking, Christine" uniqKey="Hicking C" first="Christine" last="Hicking">Christine Hicking</name>
<affiliation wicri:level="1"><mods:affiliation>Merck KGaA, Darmstadt, Germany</mods:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Merck KGaA, Darmstadt</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation wicri:level="1"><mods:affiliation>Centre Hospitalo‐universitaire de Nantes, Centre d'Investigation Clinique, Nantes, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Hospitalo‐universitaire de Nantes, Centre d'Investigation Clinique, Nantes</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
<affiliation wicri:level="1"><mods:affiliation>Ruhr University, Bochum, Germany</mods:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Ruhr University, Bochum</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nutt, John" sort="Nutt, John" uniqKey="Nutt J" first="John" last="Nutt">John Nutt</name>
<affiliation wicri:level="1"><mods:affiliation>Oregon Health Sciences University, Portland, Oregon, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Oregon Health Sciences University, Portland, Oregon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Warren Olanow, C" sort="Warren Olanow, C" uniqKey="Warren Olanow C" first="C." last="Warren Olanow">C. Warren Olanow</name>
<affiliation wicri:level="1"><mods:affiliation>Mount Sinai School of Medicine New York, New York, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mount Sinai School of Medicine New York, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><mods:affiliation>Toulouse University Hospital, INSERM Clinical Investigation Center, Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Toulouse University Hospital, INSERM Clinical Investigation Center, Toulouse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Russ, Hermann" sort="Russ, Hermann" uniqKey="Russ H" first="Hermann" last="Russ">Hermann Russ</name>
<affiliation wicri:level="1"><mods:affiliation>Merck KGaA, Darmstadt, Germany</mods:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Merck KGaA, Darmstadt</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:26A53AAFCA642D9FC0D0DC629121E408271C161E</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.21897</idno>
<idno type="url">https://api.istex.fr/document/26A53AAFCA642D9FC0D0DC629121E408271C161E/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001B15</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001B15</idno>
<idno type="wicri:Area/Istex/Curation">001B13</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Placebo influences on dyskinesia in Parkinson's disease</title>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><mods:affiliation>Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
</affiliation>
<affiliation wicri:level="2"><mods:affiliation>Rush University Medical Center, Suite 755, 1725 West Harrison Street, Chicago, IL</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>Rush University Medical Center, Suite 755, 1725 West Harrison Street, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Laska, Eugene" sort="Laska, Eugene" uniqKey="Laska E" first="Eugene" last="Laska">Eugene Laska</name>
<affiliation wicri:level="1"><mods:affiliation>New York University School of Medicine, New York, New York, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New York University School of Medicine, New York, New York</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Nathan Kline Institute, Orangeburg, New York, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Nathan Kline Institute, Orangeburg, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hicking, Christine" sort="Hicking, Christine" uniqKey="Hicking C" first="Christine" last="Hicking">Christine Hicking</name>
<affiliation wicri:level="1"><mods:affiliation>Merck KGaA, Darmstadt, Germany</mods:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Merck KGaA, Darmstadt</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation wicri:level="1"><mods:affiliation>Centre Hospitalo‐universitaire de Nantes, Centre d'Investigation Clinique, Nantes, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Hospitalo‐universitaire de Nantes, Centre d'Investigation Clinique, Nantes</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name>
<affiliation wicri:level="1"><mods:affiliation>Ruhr University, Bochum, Germany</mods:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Ruhr University, Bochum</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nutt, John" sort="Nutt, John" uniqKey="Nutt J" first="John" last="Nutt">John Nutt</name>
<affiliation wicri:level="1"><mods:affiliation>Oregon Health Sciences University, Portland, Oregon, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Oregon Health Sciences University, Portland, Oregon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Warren Olanow, C" sort="Warren Olanow, C" uniqKey="Warren Olanow C" first="C." last="Warren Olanow">C. Warren Olanow</name>
<affiliation wicri:level="1"><mods:affiliation>Mount Sinai School of Medicine New York, New York, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mount Sinai School of Medicine New York, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><mods:affiliation>Toulouse University Hospital, INSERM Clinical Investigation Center, Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Toulouse University Hospital, INSERM Clinical Investigation Center, Toulouse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Russ, Hermann" sort="Russ, Hermann" uniqKey="Russ H" first="Hermann" last="Russ">Hermann Russ</name>
<affiliation wicri:level="1"><mods:affiliation>Merck KGaA, Darmstadt, Germany</mods:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Merck KGaA, Darmstadt</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-04-15">2008-04-15</date>
<biblScope unit="volume">23</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="700">700</biblScope>
<biblScope unit="page" to="707">707</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">26A53AAFCA642D9FC0D0DC629121E408271C161E</idno>
<idno type="DOI">10.1002/mds.21897</idno>
<idno type="ArticleID">MDS21897</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term>
<term>dyskinesias</term>
<term>placebo</term>
<term>randomized clinical trials</term>
<term>sarizotan</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Clinical features that are prognostic indicators of placebo response among dyskinetic Parkinson's disease patients were determined. Placebo‐associated improvements occur in Parkinsonism, but responses in dyskinesia have not been studied. Placebo data from two multicenter studies with identical design comparing sarizotan to placebo for treating dyskinesia were accessed. Sarizotan (2 mg/day) failed to improve dyskinesia compared with placebo, but both treatments improved dyskinesia compared with baseline. Stepwise regression identified baseline characteristics that influenced dyskinesia response to placebo, and these factors were entered into a logistic regression model to quantify their influence on placebo‐related dyskinesia improvements and worsening. Because placebo‐associated improvements in Parkinsonism have been attributed to heightened dopaminergic activity, we also examined the association between changes in Parkinsonism and dyskinesia. Four hundred eighty‐four subjects received placebo treatment; 178 met criteria for placebo‐associated dyskinesia improvement and 37 for dyskinesia worsening. Older age, lower baseline Parkinsonism score, and lower total daily levodopa doses were associated with placebo‐associated improvement, whereas lower baseline dyskinesia score was associated with placebo‐associated worsening. Placebo‐associated dyskinesia changes were not correlated with Parkinsonism changes, and all effects in the sarizotan group were statistically explained by the placebo‐effect regression model. Dyskinesias are affected by placebo treatment. The absence of correlation between placebo‐induced changes in dyskinesia and Parkinsonism argues against a dopaminergic activation mechanism to explain placebo‐associated improvements in dyskinesia. The magnitude and variance of placebo‐related changes and the factors that influence them can be helpful in the design of future clinical trials of antidyskinetic agents. © 2007 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B13 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001B13 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:26A53AAFCA642D9FC0D0DC629121E408271C161E |texte= Placebo influences on dyskinesia in Parkinson's disease }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |